|
Orthologous residues
|
|
p53 (human): S46‑p, p53 (mouse): L43‑p, p53 iso2 (mouse): L46‑p, p53 (rat): L48‑p, p53 (rabbit): S45‑p, p53 (monkey): S46‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
bone cancer, colorectal cancer, colorectal carcinoma
|
|
Relevant cell lines - cell types - tissues:
293T (epithelial), HCT116 (intestinal), Saos-2 (bone cell), SW480 (intestinal), U2OS (bone cell)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
DYRK2 (human)
|
transfection of wild-type enzyme, pharmacological activator of upstream enzyme, phospho-antibody, microscopy-colocalization, siRNA inhibition of enzyme, transfection of inactive enzyme, co-immunoprecipitation
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
adriamycin
|
|
|
|
increase
|
|
|
siRNA
|
adriamycin
|
ATM (human)
|
|
inhibit treatment-induced increase
|
|
|
UV
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (process):
apoptosis, induced
|
